

Fertilizers & Agricultural

India | Sector | Quarterly Preview



1 January 2026

All demand driving factors under pressure

Agrochemical companies are expected to continue their sub-par performance as most of the demand driving factors (pest infestation, crop prices, weather conditions) remain under stress. The domestic agrochemical industry is likely to see a decline in volume in Q3 as higher sales return of the *kharif* season (in October) would have offset the placement growth of the *Rabi* season. Within Fertilisers, Urea and DAP volumes are stable at +1% growth and -2% drop respectively, while NPK volumes have declined -15% for the industry.

A tale of adverse realizations, weather and crop output: In India, unseasonal and extended rainfall in October extensively damaged crop protection consumption (the last window for *Kharif* season application was also lost). Crop damages were higher than normal (also in specific crops).

Lower crop, horticulture and grain prices have reduced farmers' purchasing power, leading to lower sale of specialty crop protection chemicals as well as lower seed sales. Declining maize prices have led to crop rotation to *jowar* in some areas. Chilli, horticulture crops, especially grapes, saw a significant drop in crop protection consumption. Region-wise, South and West India saw a sharp decline in agrochemical demand, while East and North are stable markets. Channel inventory is also elevated for some multinationals.

Raw material prices to hurt profitability of fertilizer companies: Within fertilizers, rising sulphur and ammonia prices are creating headwinds for fertilizer companies. To offset that, fertilizer companies have taken marginal price hike as nutrient based subsidy for Q3 is not remunerative enough. Despite price hike, we expect higher raw material prices to weigh in on the profitability of the fertilizer business for complex fertilizer manufacturers.

Continue to prefer fertilizers over agrochemicals: We continue to prefer fertilizer companies over their agrochemical counterparts due to several growth opportunities offered by the sector without any meaningful risk. **We like UPLL and SUMICHEM with the agrochemical sector. Within fertilizers, we like Coromandel International, PARADEEP and Chambal Fertilisers.**

Company	Revenue (INR mn)		
	FY26E	FY27E	FY28E
PI Ind	84,466	91,223	98,521
UPL	503,620	548,728	598,093
Bayer CropScience	58,018	62,659	67,672
Sumitomo Chemicals	34,340	38,972	43,123
Dhanuka Agritech	21,006	25,038	29,661
Rallis India	28,599	31,221	33,976
Insecticides India	21,199	24,379	26,817
Coromandel International	321,442	331,669	357,731
Chambal Fertilisers	167,017	176,002	180,620
Paradeep Phosphates	219,320	224,480	230,083

Company	Adjusted PAT (INR mn)		
	FY26E	FY27E	FY28E
PI Ind	17,753	19,825	22,056
UPL	29,591	48,431	63,175
Bayer CropScience	6,251	6,904	7,609
Sumitomo Chemicals	5,834	6,989	8,059
Dhanuka Agritech	3,048	3,831	4,805
Rallis India	1,956	2,631	3,317
Insecticides India	1,543	1,897	2,012
Coromandel International	22,883	28,905	32,401
Chambal Fertilisers	20,026	22,576	19,797
Paradeep Phosphates	14,754	13,180	15,822

Source: Elara Securities Estimates

Prashant Biyani

Fertilizers & Agricultural Chemicals, Hotels, Sugar
+91 22 6164 8581
prashant.biyani@elaracapital.com

Associates

Yashi Jain
yashi.jain@elaracapital.com

Rahul Bhadoriya
rahul.bhadoriya@ElaraCapital.com



Elara Fertilizers & Agricultural universe – Coverage matrix

Company	Ticker	Rating	Mcap	CMP	TP	Upside	P/E (x)				EV/EBITDA (x)				ROE (%)			
			(USD mn)	(INR)	(INR)	(%)	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E
UPL	UPLL IN	BUY	7,395	787	980	24	48.0	21.2	12.9	9.9	12.8	10.4	8.5	7.2	3.7	7.9	12.6	15.0
PI Industries	PI IN	ACCUMULATE	5,380	3,184	4,023	26	29.2	27.3	24.4	21.9	20.5	19.2	17.3	15.8	17.6	16.6	16.4	15.0
Bayer CropScience	BYRCS IN	ACCUMULATE	2,260	4,514	6,278	39	35.7	32.5	29.4	26.7	28.5	24.2	22.0	20.1	19.9	24.1	25.9	27.0
Sumitomo Chemical India	SUMICHEM IN	BUY	2,576	463	698	51	45.8	39.7	33.1	28.7	34.9	30.8	26.0	22.8	18.9	20.2	20.5	19.0
Dhanuka Agritech	DAGRI IN	BUY	591	1,178	2,106	79	17.9	17.4	13.9	11.1	12.5	11.9	9.8	7.9	22.3	23.9	24.4	24.0
Rallis India	RALI IN	ACCUMULATE	601	278	401	44	42.5	27.0	20.1	15.9	17.6	14.4	11.4	9.6	6.6	11.3	13.3	14.0
Insecticides India	INST IN	ACCUMULATE	229	706	908	29	14.7	13.5	11.0	10.4	10.2	9.3	7.6	7.1	13.5	15.5	14.5	13.0
Coromandel International	CRIN IN	BUY	7,348	2,237	2,737	22	38.3	28.8	22.8	20.3	24.2	18.9	15.3	14.0	16.6	19.4	23.1	21.0
Chambal Fertilisers	CHMB IN	ACCUMULATE	2,107	472	601	27	11.5	9.4	8.4	9.6	7.3	6.5	5.8	6.7	20.7	21.6	21.0	15.0
Paradeep Phosphates	PARADEEP IN	BUY	1,502	165	238	44	24.4	11.6	13.0	10.8	14.2	7.0	7.6	6.7	14.4	26.4	16.7	16.0

Note: Pricing as on 31 December 2025; Source: Company, Elara Securities Estimate

Exhibit 1: Peer financials

	Revenue (INR mn)					EBITDA (INR mn)					Adjusted net profit (INR mn)				
	Q3FY26E	Q2FY26	Q3FY25	QoQ(%)	YoY (%)	Q3FY26E	Q2FY26	Q3FY25	QoQ(%)	YoY (%)	Q3FY26E	Q2FY26	Q3FY25	QoQ(%)	YoY (%)
PI Ind	16,081	18,723	19,008	(14.1)	(15.4)	4,054	5,413	5,119	(25.1)	(20.8)	2,982	4,093	3,726	(27.1)	(20.0)
UPL	140,509	120,190	109,070	16.9	28.8	21,879	20,010	19,560	9.3	11.9	4,491	4,110	3,120	9.3	43.9
Bayer CropScience	10,780	15,534	10,569	(30.6)	2.0	569	2,053	197	(72.3)	188.8	452	1,527	342	(70.4)	32.1
Sumitomo Chemicals	6,147	9,144	6,224	(32.8)	(1.2)	971	2,170	1,011	(55.2)	(3.9)	884	1,779	1,908	(50.3)	(53.7)
Dhanuka Agritech	4,096	5,982	4,453	(31.5)	(8.0)	663	1,367	756	(51.5)	(12.2)	428	940	551	(54.5)	(22.3)
Rallis India	5,245	8,610	5,220	(39.1)	0.5	422	1,540	440	NA	(4.2)	150	960	110	(84.4)	36.6
Insecticides India	3,808	6,377	3,592	(40.3)	6.0	291	895	287	(67.5)	1.3	137	591	152	(76.9)	(10.3)
Coromandel International	80,507	96,541	69,352	(16.6)	16.1	7,307	11,465	7,218	(36.3)	1.2	4,860	8,053	5,118	(39.6)	(5.0)
Chambal Fertilisers	57,329	64,128	49,181	(10.6)	16.6	8,070	8,417	7,779	(4.1)	3.7	5,931	6,488	5,344	(8.6)	11.0
Paradeep Phosphates	49,051	68,722	41,049	(28.6)	19.5	4,061	6,566	3,363	(38.1)	20.8	1,629	3,419	1,587	(52.4)	2.6

Source: Company, Elara securities Estimate

Exhibit 2: DAP closing stock higher, driven by imports

Product (mn MT)	18-Dec-23	19-Dec-24	19-Dec-25	YoY (%)
UREA	60.5	54.9	42.7	(22.2)
DAP	13.0	9.6	16.3	70.2
MOP	6.6	8.5	6.2	(27.8)
NPK	32.3	23.3	34.7	48.6
Complex	14.3	17.7	18.6	5.6

Source: Department of Fertilisers, Elara Securities Research

Exhibit 3: Urea volumes are stable while phosphatic fertilizer sales are under pressure

Mn Tonnes	Oct-19th Dec 2025	Oct-19th Dec 2024	YoY (%)
Urea	9.0	9.0	0.9
DAP	3.4	3.5	(2.5)
NPK	0.6	0.7	(14.8)
MoP	3.5	4.0	(12.1)
SSP	1.5	1.6	(5.0)

Source: Department of Fertilisers, Elara Securities Research

Exhibit 4: Realization of all crop categories under pressure

Crop	Price (INR/ quintal)			YoY (%)			MoM (%)		
	Oct-25	Nov-25	Dec-25	Oct-25	Nov-25	Dec-25	Oct-25	Nov-25	Dec-25
Pulses									
Green Gram Moong	9,858	10,046	9,926	(18.4)	0.3	0.0	(0.8)	1.9	(1.2)
Black Gram Urd beans	6,110	6,300	6,209	(20.2)	(11.9)	(12.5)	(6.0)	3.1	(1.5)
Arhar (Tur)	7,963	7,973	7,856	(36.5)	(21.5)	(17.1)	0.6	0.1	(1.5)
Cotton	6,856	7,123	7,381	(2.8)	(0.4)	3.2	(2.8)	3.9	3.6
Soyabean	3,960	4,353	4,440	(26.0)	5.8	8.9	(4.4)	9.9	2.0
Coarse Cereals									
Maize	1,854	1,763	1,813	(14.4)	(20.5)	(20.0)	(9.9)	(5.0)	2.9
Bajra	2,329	2,420	2,482	(1.7)	(6.8)	(5.4)	4.8	3.9	2.6
Jowar	2,977	3,272	3,710	2.6	10.9	17.6	2.8	9.9	13.4
Paddy	2,146	2,275	2,310	(10.7)	(0.4)	0.7	(0.9)	6.0	1.5
Wheat	2,545	2,545	2,490	(19.0)	(18.8)	(23.8)	0.5	0.0	(2.2)
Vegetables									
Onion	928	903	1,275	(71.4)	(74.3)	(54.8)	(7.0)	(2.7)	41.1
Tomato	1,529	1,937	2,480	(54.4)	(10.6)	52.3	(3.7)	26.7	28.0
Potato	1,110	1,582	1,027	(43.6)	(21.1)	(46.9)	4.7	42.6	(35.1)
Cucumber	1,352	1,202	1,609	(48.0)	(47.7)	(32.8)	(12.0)	(11.1)	33.9
Spices									
Turmeric	11,501	12,742	13,131	(5.6)	5.2	11.6	8.3	10.8	3.0
Red Chilly	8,102	14,114	13,402	(50.8)	(0.7)	50.0	(26.7)	74.2	(5.0)


Source: Department of Agriculture, Elara Securities Research

Exhibit 5: Total *rabi* sowing up 1% till date


Crop (mn Ha)	2025	2024	YoY (%)
Rabi crop sowing as on 26th December 2025			
Wheat	32.3	32.2	0.1
Rice	1.5	1.3	14.5
Pulses	13.3	13.0	2.8
Gram	9.6	9.1	5.1
Lentil	1.7	1.7	1.2
Fieldpea	0.8	0.8	(4.2)
Kulthi	0.2	0.2	(22.7)
Urdbean	0.4	0.4	(6.0)
Moongbean	0.1	0.1	4.0
Lathyrus	0.3	0.3	(0.7)
Other Pulses	0.4	0.4	(2.6)
Shri Anna & Coarse cereals	4.9	4.9	0.2
Jowar	2.0	2.2	(7.4)
Bajra	0.0	0.0	(8.3)
Ragi	0.1	0.0	40.8
Small Millets	0.0	0.0	44.4
Maize	2.1	2.0	4.0
Barley	0.7	0.6	11.5
Oilseeds	9.4	9.3	1.1
Rapeseed & Mustard	8.8	8.7	1.4
Groundnut	0.3	0.3	(15.8)
Safflower	0.1	0.1	29.7
Sunflower	0.0	0.0	32.4
Sesamum	0.0	0.0	(18.2)
Linseed	0.2	0.2	(0.5)
Other Oilseeds	0.0	0.0	20.7
Total Crops	61.4	60.7	1.1

Source: Department of Agriculture, Elara Securities Research


Coverage History




Date	Rating	Target Price (INR)	Closing Price (INR)
08-May-2023	Buy	936	715
31-Jul-2023	Buy	873	625
30-Oct-2023	Buy	653	539
02-Feb-2024	Sell	491	534
06-Mar-2024	Reduce	491	473
13-May-2024	Accumulate	597	534
03-Feb-2025	Accumulate	664	604
12-May-2025	Accumulate	749	677
01-Aug-2025	Buy	798	665
06-Nov-2025	Buy	980	733




Date	Rating	Target Price (INR)	Closing Price (INR)
03-May-2023	Accumulate	3,909	3,426
03-May-2023	Accumulate	3,794	3,274
09-Aug-2023	Accumulate	4,270	3,877
13-Dec-2023	Buy	4,270	3,427
23-May-2024	Accumulate	4,023	3,660
08-Aug-2024	Accumulate	4,817	4,457
14-Nov-2024	Accumulate	4,977	4,265
07-Feb-2025	Accumulate	4,048	3,544
20-May-2025	Accumulate	3,907	3,730
13-Aug-2025	Accumulate	4,023	3,773




Date	Rating	Target Price (INR)	Closing Price (INR)
07-Feb-2023	Buy	6,191	4,493
24-May-2023	Buy	6,000	4,118
03-Nov-2023	Buy	6,432	5,193
02-Feb-2024	Buy	7,186	5,789
23-May-2024	Buy	6,895	5,591
08-Aug-2024	Accumulate	7,678	6,925
16-Aug-2024	Buy	7,678	6,159
14-Nov-2024	Accumulate	6,443	5,893
28-May-2025	Accumulate	6,278	5,716
07-Nov-2025	Accumulate	5,167	4,592




Date	Rating	Target Price (INR)	Closing Price (INR)
01-Aug-2023	Accumulate	457	408
30-Oct-2023	Accumulate	401	381
02-Feb-2024	Accumulate	423	400
28-May-2024	Accumulate	472	449
26-Jul-2024	Accumulate	569	505
29-Oct-2024	Accumulate	600	552
28-Jan-2025	Buy	685	506
28-May-2025	Buy	666	510
05-Aug-2025	Accumulate	698	638
28-Oct-2025	Buy	633	512




Date	Rating	Target Price (INR)	Closing Price (INR)
07-Nov-2023	Accumulate	963	874
02-Feb-2024	Reduce	1,115	1,130
06-Mar-2024	Buy	1,287	1,028
17-May-2024	Accumulate	1,417	1,334
02-Aug-2024	Accumulate	2,106	1,821
06-Nov-2024	Accumulate	1,821	1,617
04-Feb-2025	Buy	1,821	1,385
20-May-2025	Buy	1,987	1,614
01-Aug-2025	Buy	2,106	1,646
31-Oct-2025	Accumulate	1,628	1,374




Date	Rating	Target Price (INR)	Closing Price (INR)
26-Apr-2023	Reduce	194	191
17-Jul-2023	Sell	194	125
26-Oct-2023	Reduce	219	217
24-Jan-2024	Reduce	246	260
23-Apr-2024	Accumulate	305	271
23-Jul-2024	Accumulate	380	343
17-Jan-2025	Accumulate	305	290
24-Apr-2025	Accumulate	256	243
15-Jul-2025	Accumulate	401	353
16-Oct-2025	Accumulate	313	284




Date	Rating	Target Price (INR)	Closing Price (INR)
30-Sep-2022	Reduce	645	718
07-Nov-2022	Sell	678	739
14-Feb-2023	Accumulate	659	583
31-May-2023	Accumulate	469	445
11-Aug-2023	Reduce	469	470
03-Nov-2023	Reduce	502	520
06-Feb-2024	Accumulate	629	593
06-Mar-2024	Buy	629	517
30-May-2024	Accumulate	593	531
17-Nov-2025	Accumulate	726	679



Date	Rating	Target Price (INR)	Closing Price (INR)
09-Aug-2024	Accumulate	1,904	1,694
25-Oct-2024	Buy	2,041	1,600
25-Oct-2024	Buy	2,041	1,600
31-Jan-2025	Accumulate	2,103	1,810
31-Jan-2025	Accumulate	2,103	1,810
28-Mar-2025	Accumulate	2,317	1,982
28-Mar-2025	Accumulate	2,317	1,982
02-May-2025	Accumulate	2,383	2,250
25-Jul-2025	Accumulate	2,737	2,443
31-Oct-2025	Buy	2,601	2,125



Date	Rating	Target Price (INR)	Closing Price (INR)
02-Nov-2022	Buy	385	308
29-May-2023	Accumulate	314	286
06-Feb-2024	Reduce	345	358
08-May-2024	Reduce	397	405
06-Aug-2024	Reduce	516	492
06-Feb-2025	Accumulate	554	520
28-Mar-2025	Reduce	625	626
13-May-2025	Sell	601	658
01-Aug-2025	Accumulate	619	518
06-Nov-2025	Accumulate	544	482



Date	Rating	Target Price (INR)	Closing Price (INR)
04-Aug-2023	Accumulate	71	65
07-Feb-2024	Accumulate	84	76
16-May-2024	Accumulate	78	70
02-Aug-2024	Buy	112	88
29-Oct-2024	Buy	129	95
05-Feb-2025	Buy	136	111
31-Mar-2025	Buy	147	103
08-May-2025	Accumulate	147	138
30-Jul-2025	Accumulate	238	209
07-Nov-2025	Buy	238	174

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/> and Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India
Elara Securities (India) Private Limited
 One International Center, Tower 3,
 21st Floor, Senapati Bapat Marg,
 Elphinstone Road (West)
 Mumbai – 400 013, India
 Tel : +91 22 6164 8500

Europe
Elara Capital Plc.
 6th Floor, The Grove,
 248A Marylebone Road,
 London, NW1 6JZ,
 United Kingdom
 Tel : +44 20 7486 9733

USA
Elara Securities Inc.
 230 Park Avenue, Suite 2415,
 New York, NY 10169, USA
 Tel: +1 212 430 5870
 Fax: +1 212 208 2501

Asia / Pacific
Elara Capital (Asia) Pte.Ltd.
 One Marina Boulevard,
 Level 20,
 Singapore 018989
 Tel : +65 6978 4047



**Managing
Director**

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of
Research**

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &
Australia**

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate
Access,
Conference &
Events**

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#)

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500

CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933

Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236

Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018

Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509

Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509